Regeneron Pharmaceuticals market cap is $69 b, and annual revenue was $7.86 b in FY 2019

Regeneron Pharmaceuticals Net income (Q1, 2020)624.6 M

Regeneron Pharmaceuticals EBIT (Q1, 2020)700.1 M

Regeneron Pharmaceuticals Cash, 31-Mar-20202.2 B

Regeneron Pharmaceuticals EV67.5 B

Regeneron Pharmaceuticals revenue was $7.86 b in FY, 2019 which is a 17.2% year over year increase from the previous period.

Regeneron Pharmaceuticals revenue breakdown by business segment: 33.3% from Sanofi and Bayer Collaboration, 61.5% from Product Sales and 5.3% from Other

USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|

## Revenue | 4.9b | 5.9b | 6.7b | 7.9b |

| 18% | 21% | 14% | 17% |

## Cost of goods sold | 299.7m | 397.1m | 434.1m | 782.2m |

## Gross profit | 4.6b | 5.5b | 6.3b | 7.1b |

| 94% | 93% | 94% | 90% |

## R&D expense | 2.1b | 2.1b | 2.2b | 3.0b |

## General and administrative expense | 1.2b | 1.3b | 1.6b | 1.8b |

## Operating expense total | 3.3b | 3.6b | 3.7b | 4.9b |

## EBIT | 1.3b | 2.1b | 2.5b | 2.2b |

| 27% | 35% | 38% | 28% |

## Interest expense | 7.2m | 25.1m | 28.2m | 30.2m |

## Pre tax profit | 1.3b | 2.1b | 2.6b | 2.4b |

## Income tax expense | 434.3m | 880.0m | 109.1m | 313.3m |

## Net Income | 895.5m | 1.2b | 2.4b | 2.1b |

USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 |
---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 1.3b | 1.5b | 1.5b | 1.5b | 1.6b | 1.7b | 1.7b | 1.9b | 2.0b | 1.8b |

## Cost of goods sold | 84.2m | 102.9m | 104.2m | 114.9m | 91.7m | 110.4m | 179.2m | 152.5m | 226.6m | |

## Gross profit | 1.2b | 1.4b | 1.4b | 1.4b | 1.5b | 1.6b | 1.5b | 1.8b | 1.8b | |

| 94% | 93% | 93% | 92% | 94% | 93% | 90% | 92% | 89% | |

## R&D expense | 507.4m | 510.0m | 529.7m | 498.6m | 529.3m | 557.0m | 641.8m | 1.0b | 663.4m | 583.9m |

## General and administrative expense | 296.8m | 306.9m | 306.8m | 330.8m | 364.9m | 369.2m | 410.8m | 417.3m | 419.9m | 367.3m |

## Operating expense total | 827.2m | 877.7m | 894.4m | 875.0m | 894.2m | 926.2m | 1.1b | 1.5b | 1.1b | 951.2m |

## EBIT | 430.5m | 550.3m | 559.9m | 567.2m | 622.2m | 626.9m | 480.0m | 315.6m | 738.5m | 700.1m |

| 33% | 37% | 37% | 38% | 39% | 38% | 28% | 16% | 36% | 38% |

## Interest expense | 7.5m | 5.4m | 6.2m | 6.4m | 6.9m | 7.5m | 7.7m | 8.0m | 7.8m | |

## Pre tax profit | 432.3m | 525.9m | 565.6m | 585.4m | 656.1m | 635.9m | 546.1m | 224.7m | 768.5m | 668.6m |

## Income tax expense | 183.4m | 138.1m | 177.3m | 107.4m | 104.7m | 41.2m | 85.0m | 31.6m | 98.9m | |

## Net Income | 248.9m | 387.7m | 388.3m | 478.0m | 551.4m | 594.7m | 461.1m | 193.1m | 669.6m | 624.6m |

USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|

## Cash | 535.2m | 812.7m | 1.5b | 1.6b |

## Accounts Receivable | 1.6b | 2.0b | 2.2b | 2.7b |

## Prepaid Expenses | 130.5m | 225.0m | 243.3m | 387.1m |

## Inventories | 399.4m | 726.1m | 1.2b | 1.4b |

## Current Assets | 3.2b | 4.3b | 6.4b | 7.7b |

## PP&E | 2.1b | 2.4b | 2.6b | 2.9b |

## Total Assets | 7.0b | 8.8b | 11.7b | 14.8b |

## Accounts Payable | 879.1m | 815.1m | 218.2m | 418.1m |

## Short-term debt | 127.3m | |||

## Current Liabilities | 1.2b | 1.1b | 1.4b | 2.1b |

## Long-term debt | 351.6m | 703.5m | 708.5m | 713.9m |

## Total Debt | 478.8m | 703.5m | 708.5m | 713.9m |

## Total Liabilities | 2.5b | 2.6b | 3.0b | 3.7b |

## Common Stock | 110.0k | 112.0k | 100.0k | 100.0k |

## Additional Paid-in Capital | 3.0b | 3.5b | 3.9b | 4.4b |

## Retained Earnings | 1.7b | 2.9b | 5.3b | 7.4b |

## Total Equity | 4.4b | 6.1b | 8.8b | 11.1b |

## Debt to Equity Ratio | 0.1 x | 0.1 x | 0.1 x | 0.1 x |

## Debt to Assets Ratio | 0.1 x | 0.1 x | 0.1 x | 0 x |

## Financial Leverage | 1.6 x | 1.4 x | 1.3 x | 1.3 x |

USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|

## Net Income | 895.5m | 1.2b | 2.4b | 2.1b |

## Depreciation and Amortization | 104.7m | 145.5m | 148.2m | 210.3m |

## Accounts Receivable | (143.8m) | (362.7m) | (268.9m) | (473.1m) |

## Inventories | (149.8m) | (314.2m) | (387.9m) | (335.5m) |

## Accounts Payable | 254.0m | (23.2m) | 210.0m | 444.5m |

## Cash From Operating Activities | 1.5b | 1.3b | 2.2b | 2.4b |

## Capital Expenditures | (511.9m) | (272.6m) | (383.1m) | (429.6m) |

## Cash From Investing Activities | (1.0b) | (1.0b) | (1.5b) | (2.0b) |

## Long-term Borrowings | 40.6m | (19.9m) | ||

## Cash From Financing Activities | (700.4m) | (24.4m) | (77.1m) | (252.1m) |

## Net Change in Cash | (273.9m) | 277.5m | 655.0m | 150.1m |

## Interest Paid | 5.5m | 18.7m | 22.3m | 25.0m |

## Income Taxes Paid | 481.4m | 754.8m | 205.6m | 342.3m |

## Free Cash Flow | 961.5m | 1.0b | 1.8b | 2.0b |

USD | Y, 2020 |
---|---|

## EV/EBIT | 96.4 x |

## Financial Leverage | 1 x |

FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | |
---|---|---|---|---|

## Cell Culture Capacity, liters | 97 k | 101 k | 100 k | 230 k |

## Facility Space Leased, square feet | 1.18 m | 1.47 m | 1.47 m | 1.47 m |

## Facility Space Owned, square feet | 1.56 m | 1.61 m | 1.61 m | 1.35 m |

## Patents (EU) | 3 | 7 | 11 | 11 |

## Patents (US) | 6 | 17 | 18 | 21 |

## Product Candidates | 16 | 15 | 21 | 22 |

## Products | 5 | 6 | 7 | 7 |

## Trademarks | 8 | 9 | 12 | 13 |